Transplant Oncology: Immuno-Oncology for Transplant Patients

Solid organ transplant recipients are at 3-10 times higher risk of cancer compared to non-transplant patients, due to long-standing immunosuppression. Cancer immunotherapy has become a standard therapy for many cancers, but its use in transplant patients is challenging because of safety and efficacy concerns. While there has been a growing data on Immuno-Oncology (IO) in transplant population, the consensus on IO use in this vulnerable population is lacking. The goals of our conference are to understand the cancer burden in transplant recipients, to learn up-to-date cancer treatment options for transplant patients, and to learn patients’ perspectives from those living with cancer post-transplant.